Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Sarcoma 2Gastrointestinal 2Tumor-Agnostic 1Head & Neck 1

Conditions

Chondrosarcoma 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × IPI-926 × Sarcoma × Clear all
NCT01310816 2013-12-05

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled
Sarcoma

Bone Neoplasms

NCT01609179 2012-11-14

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Infinity Pharmaceuticals, Inc.

Phase NA Completed
9 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡